The market for Alzheimer’s disease (AD) pharmacotherapies represents an enormous commercial opportunity driven by considerable unmet need and looming societal burden. The AD population is…
There is increased industry focus on the behavioral symptoms of Alzheimer’s disease (AD), including agitation—and with good reason. Agitation affects the majority of diagnosed AD patients,…
Market Outlook: Despite advancements in the treatment landscape for first-line CLL with targeted agents such as Imbruvica, Zydelig, and Gazyva/Gazyvaro, it remains largely an incurable disease…
Patients with osteoporosis and osteopenia are at increased risk of suffering fractures. These fractures place a considerable burden on public health systems, and significant unmet need remains in…
Abstract: Owing to the large diagnosed prevalent population, relatively high rates of drug treatment across patients of all disease severities, and high rates of polypharmacy—particularly among…
Geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD), is a leading cause of visual impairment and blindness in the United States and Europe. Degradation of cells…
Acute myeloid leukemia is the most common form of acute leukemia in adults. Its incidence in the major pharmaceutical markets under study is increasing, largely as a result of the aging population…
Dravet syndrome (DS) is a rare, severe, pediatric-onset form of epilepsy characterized by developmental delay or regression and multiple seizure types. Only Diacomit (Biocodex’s stiripentol) is…
Osteoarthritis (OA) is a painful, degenerative condition that is characterized by the gradual development of joint pain, as well as joint stiffness and limitation of movement in the joints. Of…
The large therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand and is expected to grow from approximately $15…
The schizophrenia therapy market is mature and very crowded given the presence of numerous atypical and typical antipsychotic agents, including the continued genericization of key oral therapies,…
The renal anemia market will expand over our 2016-2026 study period, fueled by increasing prevalence and a high unmet need for drugs that can effectively, safely, and conveniently control the…
The hospital-treated gram-negative infection (GNI) market is dominated by highly effective, generically available antibiotics. However, the rising prevalence of multidrug-resistant (MDR) pathogens…
Although motor fluctuations in Parkinson’s disease (PD) can be managed effectively in the early stages of the disease, today’s treatment paradigm is suboptimal owing to the considerable pill…
Treatment of BRAF-mutation-positive unresectable or metastatic malignant melanoma has been transformed in recent years by the identification of BRAFmutations and the development of BRAF and MEK…